Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448669 · ClinicalTrials.gov registry record · Phase 2
Botswana TDF/FTC Oral HIV Prophylaxis Trial
A Phase 2 study of HIV Infections, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,219
- Enrollment target
- 2
- Study locations
NCT00448669: Completed Phase 2 study of HIV Infections, sponsored by Centers for Disease Control and Prevention.
NCT00448669 is a Phase 2 study of HIV Infections that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 1,219 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (175% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00448669, a Phase 2 study of HIV Infections, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,219 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV infection.
Primary Outcome
Study visits were scheduled every 30 days until completion of the study, and participants were instructed to return to the clinic for evaluation in the event of an illness. Participants reported any adverse effects at monthly visits and interim visits.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Study Locations (2)
Georgia
- Centers for Disease Control and Prevention - Atlanta
Other
- BOTUSA HIV Prevention Research Unit - Gaborone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,219 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT00448669 record still lists
NCT00448669 is an interventional study that assigns participants to a tested intervention. Its 1,219 participants enrollment target places it among the larger protocols in the corpus, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (175% higher).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT00448669 reports a single indexed study location in Georgia, Other.
Frequently Asked Questions
What is clinical trial NCT00448669 about?
NCT00448669 is a clinical study titled "Botswana TDF/FTC Oral HIV Prophylaxis Trial". This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV infection.
What is the current status of trial NCT00448669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,219 participants. The study started on 2007-03. Estimated completion is 2011-03.
What conditions does trial NCT00448669 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00448669?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (DRUG).
Who is sponsoring clinical trial NCT00448669?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00448669 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00448669's enrollment target sits among peer trials
1,219 21st of 542 higher than 522 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia